Although certain therapeutic agents, such as angiotensin-converting enzyme (ACE) inhibitors and sodium-dependent glucose transporters 2 (SGLT2) inhibitors, have shown promise in managing the complications of diabetic nephropathy, their clinical utility is often questioned due to poor solubility, low bioavailability, inability to halt disease progression despite symptom alleviation, and low patient adherence (Paul et al., 2023; Amanat et al., 2025; Cherney et al., 2025). This evidence concerns the gene SLC5A2 and diabetic kidney disease.